Revolution Medicines, Inc. (NASDAQ:RVMDW – Get Free Report) traded up 2.2% on Wednesday . The company traded as high as $6.68 and last traded at $6.40. 57,743 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 138,515 shares. The stock had previously closed at $6.26.
Revolution Medicines Stock Performance
The firm has a 50-day moving average of $5.30 and a 200-day moving average of $2.94.
Revolution Medicines Company Profile
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
Featured Articles
- Five stocks we like better than Revolution Medicines
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
- Why Palantir’s Google Cloud Deal Could Change the Debate
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
